TickerFacts.

Trevi Therapeutics, Inc. (TRVI): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$49.18M
Year ended 2025-12-31
-$59.42M
Trailing 12 months to 2026-06-30
2022-12-31: -$29.86M2023-12-31: -$33.80M2024-12-31: -$51.38M2025-12-31: -$49.18M-$49.18M
2022-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$49.18Mn/m2026-03-17, From 2025-01-01
2024-12-31-$51.38Mn/m2026-03-17, From 2024-01-01
2023-12-31-$33.80Mn/m2025-03-18, From 2023-01-01
2022-12-31-$29.86Mn/a2024-03-20, From 2022-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Trevi Therapeutics, Inc. (TRVI)2025-12-31-$49.18Mn/m
Adicet Bio, Inc. (ACET)2025-12-31-$115.73Mn/m
Foghorn Therapeutics Inc. (FHTX)2025-12-31-$83.06Mn/m
UroGen Pharma Ltd. (URGN)2025-12-31-$124.56Mn/m
Lexicon Pharmaceuticals, Inc. (LXRX)2025-12-31-$48.29Mn/m
Alto Neuroscience, Inc. (ANRO)2024-12-31-$68.11Mn/m
Benitec Biopharma Inc. (BNTC)2026-06-30-$51.13Mn/m
PepGen Inc. (PEPG)2025-12-31-$92.21Mn/m
Puma Biotechnology, Inc. (PBYI)2025-12-31$48.24M+13.5%

Compare TRVI, ACET, FHTX, URGN side by side · Screen every company in Pharmaceutical Preparations ↗